<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37714616</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>18</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1558-0512</ISSN><JournalIssue CitedMedium="Internet"><Volume>67</Volume><Issue>4</Issue><PubDate><Year>2023</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Dental clinics of North America</Title><ISOAbbreviation>Dent Clin North Am</ISOAbbreviation></Journal><ArticleTitle>Scaling and Root Planning in a Patient Taking Chronic Corticosteroid Therapy for Lupus Erythematosus.</ArticleTitle><Pagination><StartPage>649</StartPage><EndPage>651</EndPage><MedlinePgn>649-651</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cden.2023.05.018</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0011-8532(23)00087-3</ELocationID><Abstract><AbstractText>The dental provider should be aware of the oral manifestations of systemic lupus erythematosus (SLE). Patients with SLE may be on chronic oral corticosteroids, which can increase the risk for periodontitis and opportunistic oral infections in addition to inducing multiple systemic adverse effects. Disease complications such as lupus nephritis and comorbid antiphospholipid antibody syndrome can further impact dental decision-making including around medications to prescribe or hemostatic measures to employ during treatment. Patients with SLE on systemic corticosteroid therapy usually do not require steroid supplementation before or after non-surgical or surgical dental treatment.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mirfendereski</LastName><ForeName>Payam</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Oral Medicine, University of Pennsylvania School of Dental Medicine, 240 South 40th Street, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Magee</LastName><ForeName>Rogan</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Penn Medicine, 3400 Spruce Street, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>France</LastName><ForeName>Katherine</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Oral Medicine, University of Pennsylvania School of Dental Medicine, 240 South 40th Street, Philadelphia, PA 19104, USA. Electronic address: kfrance@upenn.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dent Clin North Am</MedlineTA><NlmUniqueID>0217440</NlmUniqueID><ISSNLinking>0011-8532</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064420" MajorTopicYN="Y">Drug-Related Side Effects and Adverse Reactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009894" MajorTopicYN="Y">Opportunistic Infections</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Autoimmune disease</Keyword><Keyword MajorTopicYN="N">Chronic corticosteroids</Keyword><Keyword MajorTopicYN="N">Immunosuppression</Keyword><Keyword MajorTopicYN="N">Oral manifestations</Keyword><Keyword MajorTopicYN="N">Systemic lupus erythematosus</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>18</Day><Hour>12</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>16</Day><Hour>5</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>15</Day><Hour>20</Hour><Minute>57</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37714616</ArticleId><ArticleId IdType="doi">10.1016/j.cden.2023.05.018</ArticleId><ArticleId IdType="pii">S0011-8532(23)00087-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>